Indeed, the expression of p-mTOR and p-AKT was significantly downregulated in SNU-449 and HepG2 cells co-treated with Ezetimibe and Sorafenib compared to HCC cells treated with Ezetimibe or Sorafenib alone (Figure 7G and Figure S8). This evidence concerns the gene AKT1 and hepatocellular carcinoma.